Reaction

Non-Small Cell Lung Cancer reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,668 reports · 84 co-occurring drugs

As of the last recalculation, Non-Small Cell Lung Cancer appears in 4,668 FAERS reports alongside 84 co-occurring drug terms. The strongest observed disproportionality signal is CRIZOTINIB (PRR 105.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Crizotinib	282	105.2	107.6
Pemetrexed	332	74.2	75.4
Pemetrexed Disodium	397	50.7	51.2
Erlotinib Hydrochloride	137	50.3	50.8
Erlotinib	82	38.4	38.7
Ipilimumab	306	33.8	34.0
Carboplatin	665	27.1	27.2
Osimertinib	169	24.4	24.5
Gefitinib	44	21.9	22.0
Nivolumab	419	21.1	21.2
Paclitaxel	387	18.9	19.0
Dabrafenib	82	17.6	17.7
Paclitaxel (Aibumin-Bound)	303	17.5	17.6
Trametinib	78	14.6	14.7
Atezolizumab	123	14.5	14.5
Gemcitabine	80	9.2	9.2
Docetaxel Anhydrous	135	9.2	9.2
Docetaxel	135	9.2	9.2
Durvalumab	40	8.8	8.8
Cisplatin	140	8.2	8.2
Magnesium Oxide	74	8.0	8.0
Gemcitabine Hydrochloride	87	7.4	7.4
Bevacizumab	191	7.1	7.1
Febuxostat Tablets 40 Mg	16	7.0	7.0
Febuxostat Tablets 80 Mg	16	7.0	7.0
Dronabinol	12	6.7	6.7
Granisetron Hydrochloride	15	6.4	6.4
Granisetron	13	5.5	5.5
Nintedanib	38	5.4	5.4
Axicabtagene Ciloleucel	12	5.4	5.4
Standardized Senna Concentrate	14	5.0	5.0
Sorafenib	23	5.0	5.0
Bendamustine Hcl	17	4.9	4.9
Benzonatate	18	4.9	4.9
Telmisartan	19	4.8	4.8
Lubiprostone	10	4.7	4.7
Pembrolizumab	107	4.6	4.6
Ursosiol	20	4.6	4.6
Diphenoxylate Hydrochloride And Atropine Sulfate	14	4.6	4.6
Febuxostat	17	4.5	4.5
Bendamustine Hydrochloride	12	4.5	4.5
Brentuximab Vedotin	10	4.4	4.4
Docusate Sodium 100Mg	23	4.3	4.3
Acetylcysteine	9	4.3	4.3
Ursodiol	20	4.1	4.1
Fondaparinux Sodium	7	3.9	3.9
Fludarabine Phosphate	33	3.8	3.8
Sennosides 8.6 Mg Tablets	17	3.6	3.6
Senna	17	3.6	3.6
Sennosides	24	3.6	3.6
Dexamethasone Sodium Phosphate	8	3.5	3.5
Pitavastatin Calcium	8	3.5	3.5
Senna Leaf	18	3.5	3.5
Loperamide Hcl	10	3.5	3.5
Loperamide Hydrochloride And Dimethicone	24	3.3	3.4
Naproxen Sodium Tablet, Coated	10	3.3	3.3
Naproxen Sodium, Coated Tablets	10	3.3	3.3
Naproxen Sodium 220Mg	10	3.3	3.3
Thalidomide	27	3.3	3.3
Loperamide Hydrochloride	32	3.2	3.2
Loperamide Hydrochloride Oral	7	3.1	3.1
Aprepitant	12	2.9	2.9
Cladribine	6	2.8	2.8
Etoposide	43	2.6	2.6
Filgrastim	22	2.6	2.6
Fosaprepitant Dimeglumine	8	2.6	2.6
Prochlorperazine Maleate	5	2.4	2.4
Tiotropium Bromide	71	2.3	2.3
Baricitinib	5	2.3	2.3
Dexamethasone 1.5 Mg	147	2.3	2.3
Dexamethasone	147	2.2	2.2
Cetuximab	15	2.1	2.1
Venetoclax	29	2.1	2.1
Icosapent Ethyl	4	2.1	2.1
Ibrutinib	36	2.0	2.0
Olaparib	8	1.7	1.7
Morphine Sulfate	46	1.7	1.7
Inclisiran	3	1.7	1.7
Oxycodone Hydrochloride	79	1.6	1.6
Acetaminophen, Aspirin (Nsaid) And Caffeine	6	1.6	1.6
Denosumab	64	1.4	1.4
Teriflunomide	14	1.4	1.4
Pegfilgrastim	21	0.9	0.9
Pirfenidone	8	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.